Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Managing COVID-19 in pregnant women

Siara Teelucksingh, Melanie Nana, Catherine Nelson-Piercy
Breathe 2022 18: 220019; DOI: 10.1183/20734735.0019-2022
Siara Teelucksingh
1Dept of Obstetric Medicine, St Thomas’ Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: siara.teelucksingh@gstt.nhs.uk
Melanie Nana
1Dept of Obstetric Medicine, St Thomas’ Hospital, London, UK
2Dept of Women and Children's Health, King's College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Nelson-Piercy
1Dept of Obstetric Medicine, St Thomas’ Hospital, London, UK
2Dept of Women and Children's Health, King's College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Principles of management of COVID-19 in the general population apply in pregnancy with few exceptions. Clinical inertia can lead to preventable morbidity and mortality. COVID-19 vaccines are safe and should be recommended at any stage of pregnancy. https://bit.ly/3Rj8nWr

COVID-19 in pregnancy

Pregnant women are no more likely to contract coronavirus disease 2019 (COVID-19) than the background population and two-thirds of those testing positive are asymptomatic [1, 2]. Risk factors for severe infection reflect those outside pregnancy and include being unvaccinated, aged >35 years, having a body mass index >25 kg·m−2, having a medical comorbidity, being in the Black, Asian and Minority Ethnicity (BAME) population, and socioeconomic deprivation [1]. Pregnant women who develop moderate/severe disease are more likely to require hospitalisation and critical care admission, particularly in the third trimester [1].

Physiology in normal pregnancy changes to meet an increase in oxygen demand [3]. There is a 15% increase in metabolic rate, 20% increase in oxygen consumption and 40–50% increase in minute ventilation, mostly due to an increase in tidal volume as respiratory rate remains unchanged. Mechanical adaptations include diaphragmatic elevation due to the enlarging uterus, which results in decreased functional residual capacity [3]. Coupled with altered immunity and physiological vascular and haemodynamic changes, women appear to compensate substantially, but deterioration can occur precipitously [4]. A modified early warning score in maternity (Modified Early Obstetric Warning Score; MEOWS) is used to identify women at risk of deterioration and prompt early escalation. Target oxygen saturations in pregnancy are 94–98% [5].

A standard approach to investigation is recommended, including use of radiological investigations when indicated. Clinical judgement should be applied in making treatment decisions as scoring systems, such as the International Severe Acute Respiratory and Emerging Infections Consortium Coronavirus Clinical Characterisation Consortium (ISARIC4C) Mortality and Deterioration Scores [6], are not validated in pregnancy. The D-dimer assay has no role in the investigation of venous thromboembolism (VTE) in pregnancy but may be included in the standard COVID-19 admission and surveillance laboratory panel as screening for a hyperinflammatory state.

Women should be cared for by a multidisciplinary team (MDT) inclusive of obstetric physicians, respiratory physicians, virologists, obstetricians, midwives and critical care specialists. Pharmacological treatment options are rapidly expanding as further evidence-based therapies emerge. Data have shown that only 25% of pregnant women received standard treatment, even in the context of severe COVID-19 illness necessitating intensive care [7, 8]. Many of the standard therapies used in the treatment of COVID-19 are appropriate for use in pregnancy. A paucity of safety data for COVID-19 therapies in pregnancy have led to undertreatment [9, 10]. Management in pregnancy must reflect, as closely as possible, management outside pregnancy. When uncertainty exists, urgent advice should be sought through maternal medicine networks if delays in care and associated maternal morbidity and mortality are to be minimised.

Severity of COVID-19 disease

Mild disease refers to asymptomatic or symptomatic illness (cough, fever, sore throat, nasal congestion, malaise, headache, muscle pain, nausea, vomiting, diarrhoea, altered taste and smell) without dyspnoea or abnormal chest imaging [7]. Two-thirds of pregnant women will be asymptomatic. Women with mild disease should be offered surveillance in the community, considered for eligibility for pre-emptive treatment (table 1) and VTE risk assessed (figure 1).

View this table:
  • View inline
  • View popup
TABLE 1

Pharmacological therapy used in the treatment of COVID-19 in pregnancy

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Approach to clinical management of women with COVID-19 who are pregnant or up to 6 weeks postpartum. SpO2: oxygen saturation measured by pulse oximetry; RR: respiratory rate; CPAP: continuous positive airway pressure; VTE: venous thromboembolism; RCOG: Royal College of Obstetricians and Gynaecologists; ACOG: American College of Obstetricians and Gynecologists; LMWH: low molecular weight heparin; MDT: multidisciplinary team; ICU: intensive care unit; CRP: C-reactive protein; ECMO: extracorporeal membrane oxygenation. Reproduced and modified from [4] with permission.

Moderate COVID-19 disease is defined by clinical or radiological evidence of lower respiratory tract involvement with preserved oxygenation (oxygen saturation ≥94% on room air) [7]. Severe disease is characterised by hypoxaemia (oxygen saturation <94% on room air or a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FIO2) <300 mmHg), a respiratory rate >30 breaths·min−1, or lung infiltrates >50% [7]. Critical COVID-19 disease is characterised by respiratory failure, septic shock and/or multiple organ dysfunction [7]. The delta variant has been implicated in the majority of moderate, severe and critical COVID-19 disease [4].

Subtle changes in condition should be observed and care escalated in those showing signs of deterioration, manifested by increased work of breathing, respiratory rate >20 breaths·min−1, desaturation on exertion or oxygen saturation of <94% on room air. There should be a low threshold for referral for critical care in pregnant women. Escalation to critical care is recommended when FIO2 exceeds 35% [1].

Proning is not contraindicated in pregnancy and can be facilitated by optimising maternal position and supportive padding [19]. The UK Obstetric Surveillance System (UKOSS) reported that 11% of hospitalised pregnant women with COVID-19 have required intensive care unit admission, with <1% requiring extracorporeal membrane oxygenation (ECMO) [2, 20]. It is important to note that mechanical ventilation and referral for ECMO should not be withheld in pregnancy [4, 19].

Pharmacological management of COVID-19 in pregnancy

Corticosteroids

The RECOVERY trial has demonstrated that dexamethasone significantly reduces mortality in patients admitted to hospital with an oxygen requirement [11]. Prednisolone, hydrocortisone or methylprednisolone are the preferred corticosteroids for treatment of COVID-19 pneumonia in pregnancy because repeated doses of dexamethasone have been associated with neurocognitive and neurosensory disorders in childhood [21]. When maturation of the fetal lung in preterm delivery is the desired outcome, intramuscular dexamethasone and betamethasone are the agents of choice, as they are synthesised to resist metabolism and readily cross the placenta. The corticosteroid being given for COVID-19 pneumonia should be omitted on the days in which intramuscular dexamethasone or betamethasone is being given (figure 1). Blood glucose monitoring should be performed twice daily in all women receiving corticosteroid therapy due to the risk of steroid-induced gestational diabetes.

Interleukin-6 receptor antagonists

The interleukin (IL)-6 receptor antagonists tocilizumab or sarilumab are indicated in women with hypoxia (oxygen saturation <94% on room air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg·L−1) or in those admitted to critical care [12].

In utero exposure to biological agents for immunomodulation may have adverse consequences upon infants who receive live vaccines, including a predisposition to neonatal infection [22]. With COVID-19, however, because such therapy is short-term, current guidance recommends offering the bacille Calmette–Guérin (BCG) vaccination after informed discussion with the mother, particularly if the IL-6 receptor antagonist was given early in pregnancy [1].

Neutralising monoclonal antibodies

Neutralising monoclonal antibodies have been demonstrated in the RECOVERY trial to be effective, particularly in patients who had not developed innate immunity to COVID-19 [13]. Safety data are lacking in pregnancy. However, they are specifically directed towards viral proteins and therefore harm to the fetus is unlikely. To enable generation of safety data, reports of use in pregnancy should be made to a teratology information service or national registry.

Casirivimab and imdevimab (Ronapreve) should be considered in women who do not have SARS-CoV-2 IgG antibodies and are hospitalised with symptomatic COVID-19 infection due to the delta variant [23–25]. Emerging evidence indicates that the casirivimab and imdevimab preparation has significantly decreased efficacy against the omicron variant [26].

Data have shown that sotrovimab administered to non-hospitalised patients with mild/moderate disease, with at least one risk factor for disease progression, resulted in a relative risk reduction in hospitalisation or death by 85% [15]. Women considered highest risk include those with trisomy 21, solid or active metastatic cancer, haematological malignancy or stem cell transplant, chronic kidney disease stage 4–5 or renal transplant, chronic liver disease Child Pugh B–C or liver transplant, solid organ transplant, immune deficiencies, poorly controlled HIV infection, or active or unstable immune-mediated inflammatory disorders (e.g. inflammatory bowel disease, myasthenia gravis, multiple sclerosis) on B-cell depleting therapies, biologics, corticosteroids (equivalent to ≥10 mg·day−1 of prednisolone for ≥28 days), cyclophosphamide, tacrolimus or ciclosporin. Such women, with ongoing symptoms within 5 days of a positive test, who are in the community or admitted to hospital for another reason, can be offered sotrovimab as pre-emptive treatment [14].

The long-acting neutralising antibody combination of tixagevimab and cilgavimab has been demonstrated in the PROVENT trial to be efficacious as pre-exposure immunoprophylaxis in non-pregnant adults with increased risk of inadequate response to vaccination, increased risk of exposure, or both, without safety concerns [16]. Safety data within pregnancy are lacking, and as both are human IgG they have potential to cross the placenta. However, no off-target binding was detected in a cross-reactive binding assay using a protein array enriched for human embryo-fetal proteins. Thus, the Medicines and Healthcare products Regulatory Agency supports its use in pregnancy where the expected benefits outweigh the potential risks to the fetus [27].

Other therapies

Rapid advances have been made in the development of evidence-based therapies for managing COVID-19, most of which are appropriate to use in pregnancy on a benefit/risk basis. There is little evidence to support this, as pregnant women are a traditionally poorly represented group in clinical trials of medications [28].

The PRINCIPLE trial has demonstrated that inhaled budesonide can reduce the recovery time for COVID-19-positive patients being managed in primary care [29]. Inhaled corticosteroids can safely be used in pregnancy and should therefore not be avoided where indicated [30].

Numerous antiviral medications have been proposed and trialled for the treatment of COVID-19 [4]. Remdesivir was the first drug licensed for treatment of COVID-19 and reduces time to recovery in hospitalised patients [17]. Although there have been no serious safety signals, limited data exist for pregnancy safety, and remdesivir is not routinely recommended in pregnancy, but may be considered after a multidisciplinary discussion in women who are deteriorating despite standard management and have a non-omicron genotype [18].

Nirmatrelvir plus ritonavir (Paxlovid), a protease inhibitor, has been shown to significantly reduce hospital admission and mortality in a selected, high-risk, non-pregnant population, when given in the first 3 days from symptom onset, without evident safety concerns [31]. Although safety in pregnancy has not been established, ritonavir has been used safely for treatment of HIV in pregnancy. In circumstances such as in women who are clinically vulnerable or have reduced antibody protection (e.g. the non-vaccinated population), or in women with severe disease where other established treatments have been ineffective, its use might be acceptable [4].

Molnupiravir is a ribonucleoside that has broad antiviral activity against RNA viruses and is not currently recommended in pregnancy.

Baricitinib is an oral selective Janus kinase (JAK) 1/2 inhibitor with anti-inflammatory properties. In non-pregnant adults, baricitinib, combined with standard care including dexamethasone, was associated with reduced mortality in hospitalised patients with COVID-19 [32]. However, the safety of JAK inhibitors has not been established in pregnancy; therefore, treatment with baricitinib is currently not recommended for COVID-19 in pregnancy [33].

Varying outcomes have been reported for the use of convalescent plasma in COVID-19. However, neither the RECOVERY trial (which included pregnant women) nor the REMAP-CAP trial demonstrated benefit and thus convalescent plasma is not currently routinely used either in or outside pregnancy [34].

Antibiotics should not routinely be used unless there is evidence to support the presence of secondary bacterial superinfection.

Venous thromboembolism prophylaxis

COVID-19 infection is a transient risk factor for VTE in pregnancy (figure 1) [35]. Women considered appropriate for outpatient management should undergo VTE risk assessment and be prescribed prophylaxis accordingly. Women admitted to hospital with COVID-19 should be given thromboprophylaxis using weight-adjusted and risk-appropriate doses of low molecular weight heparin (LMWH) during their inpatient admission and for at least 10 days post-discharge unless contraindicated [1, 35].

Discussion with the MDT should occur if delivery is imminent as the last dose of LMWH should be withheld for 12 h in prophylaxis and 24 h in treatment of VTE, prior to spinal and epidural procedures.

Maternal and fetal monitoring

A standard approach to monitoring pregnant women should be undertaken with the use of MEOWS, with close observation paid to the work of breathing. The standard surveillance blood investigations should be performed. There should be a low threshold for computed tomography pulmonary angiography in cases of clinical deterioration, as risk of VTE remains high despite prophylactic LMWH. There should be increased surveillance for steroid-induced gestational diabetes. In women who are given IL-6 receptor antagonists, monitoring for secondary infection is required as immune response may be blunted. The INTERCOVID study demonstrated higher rates of pre-eclampsia and preterm birth in women infected with COVID-19 [36].

Fetal monitoring is provided at a woman's bedside via cardiotocography. This is recommended twice daily in hospitalised women or prompted by reduction in fetal movements [1]. A growth ultrasound scan should also be performed to assess for fetal growth restriction, informing timing of delivery. Hospitalised women who have recovered from a period of severe or critical illness with COVID-19 should be offered a fetal growth scan 2 weeks after recovery.

Mode and timing of delivery

Mode and timing of delivery should be an MDT decision [1]. In women with severe/critical disease requiring mechanical ventilation, delivery is typically offered particularly if >34 weeks gestation, usually via emergency Caesarean section. There is no evidence of benefit to improvement in ventilation, maternal or fetal outcomes if delivery is performed before 34 weeks. Critically unwell women should be offered continuous electronic fetal monitoring during delivery.

In cases in which preterm birth is expected, magnesium sulphate therapy should be administered for fetal neuroprotection until 29+6 weeks gestation. Administration of corticosteroids for fetal lung maturation should be given prior to 35 weeks gestation.

All efforts should be made to facilitate early bonding with skin-to-skin contact and breastfeeding.

Follow-up

Follow-up, usually 6 weeks after hospital discharge, is recommended to ensure resolution of disease and absence of features of long COVID. Oxygen saturations should be measured and a chest radiograph reviewed. Persistent fatigue, dyspnoea, anxiety and depression are often reported among patients who were treated for severe/critical COVID-19 pneumonia [37]. A mental health screen should be performed and perinatal mental health support considered. COVID-19 vaccination should be strongly recommended 28 days following infection in unvaccinated patients.

COVID-19 vaccination

At least 275 000 pregnant women have been vaccinated in the UK and USA with no adverse safety signals reported. No pregnant woman with COVID-19 who has received two doses of the vaccine has developed severe/critical illness requiring hospitalisation or intensive care [38]. As such, vaccination is endorsed at any stage in pregnancy [1, 4]. Most evidence exists for the mRNA vaccines and these are thus preferred in pregnancy.

Maternal deaths from COVID-19 continue to occur in unvaccinated women, with highest death rates attributable to the delta variant [4]. With the emergence of the omicron variant, a booster vaccine is recommended 3 months following the second dose, to confer additional protection [1].

There has been notable vaccine hesitancy, with many women preferring to delay vaccination until after pregnancy due to unsubstantiated concerns about infertility, harm to the fetus and vaccine-induced thrombotic thrombocytopenia, which is not only rare but idiosyncratic. Vaccination rates amongst pregnant women, particularly in those of younger age and amongst BAME populations remain low despite good evidence supporting an association between vaccination and lower odds of adverse outcomes in COVID-19 of any severity in pregnancy. Vaccines are available, effective in pregnancy and without adverse consequences towards mother or fetus. Women should not postpone vaccination until after they have given birth and should be signposted to relevant patient information at every opportunity [39].

Key points

  • The principles of management of COVID-19 in the general population apply in pregnancy with few exceptions.

  • Clinical inertia in the investigation and treatment of COVID-19 in pregnancy can lead to preventable morbidity and mortality.

  • COVID-19 vaccines are safe and should be recommended at any stage of pregnancy or when breastfeeding.

Footnotes

  • Conflict of interest: The authors have nothing to disclose.

  • Received February 22, 2022.
  • Accepted July 5, 2022.
  • Copyright ©ERS 2022
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Royal College of Obstetricians and Gynaecologists
    . Coronavirus (COVID-19) Infection in Pregnancy. Information for Healthcare Professionals. Version 14.3. Date last updated: 11 January 2022. Date last accessed: 11 February 2022. www.rcog.org.uk/coronavirus-pregnancy
  2. ↵
    1. Vousden N,
    2. Bunch K,
    3. Morris E, et al.
    The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: a national cohort study using the UK Obstetric Surveillance System (UKOSS). PLoS One 2021; 16: e0251123. doi:10.1371/journal.pone.0251123
    OpenUrlCrossRefPubMed
  3. ↵
    1. Soma-Pillay P,
    2. Nelson-Piercy C,
    3. Tolppanen H, et al.
    Physiological changes in pregnancy. Cardiovasc J Afr 2016; 27: 89–94. doi:10.5830/CVJA-2016-021
    OpenUrlCrossRefPubMed
  4. ↵
    1. Nana M,
    2. Hodson K,
    3. Lucas N, et al.
    Diagnosis and management of COVID-19 in pregnancy. BMJ 2022; 377: e069739. doi:10.1136/bmj-2021-069739
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Robbins T,
    2. Shennan A,
    3. Sandall J
    . Modified early obstetric warning scores: a promising tool but more evidence and standardization is required. Acta Obstet Gynecol Scand 2019; 98: 7–10. doi:10.1111/aogs.13448
    OpenUrl
  6. ↵
    1. Gupta RK,
    2. Harrison EM,
    3. Ho A, et al.
    Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respir Med 2021; 9: 349–359. doi:10.1016/S2213-2600(20)30559-2
    OpenUrl
  7. ↵
    1. National Institutes of Health
    . Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Date last updated: 31 May 2022. Date last accessed: 2 July 2022. www.covid19treatmentguidelines.nih.gov
  8. ↵
    1. Wong MJ,
    2. Bharadwaj S,
    3. Lankford AS, et al.
    Mechanical ventilation and prone positioning in pregnant patients with severe COVID-19 pneumonia: experience at a quaternary referral center. Int J Obstet Anesth 2022; 49: 103236. doi:10.1016/j.ijoa.2021.103236
    OpenUrl
  9. ↵
    1. Population Health, National Perinatal Epidemiology Unit
    1. Oxford
    Population Health, National Perinatal Epidemiology Unit. UKOSS Key information on COVID-19 in pregnancy. Date last updated: 11 October 2021. Date last accessed: 11 February 2022. www.npeu.ox.ac.uk/news/2171-covid-19-in-pregnancy-2
  10. ↵
    1. Camporota L,
    2. Meadows C,
    3. Ledot S, et al.
    Consensus on the referral and admission of patients with severe respiratory failure to the NHS ECMO service. Lancet Respir Med 2021; 9: e16–e17. doi:10.1016/S2213-2600(20)30581-6
    OpenUrl
  11. ↵
    1. Horby P,
    2. Lim WS, et al.
    1. RECOVERY Collaborative Group
    , Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384: 693–704. doi:10.1056/NEJMoa2021436
    OpenUrlCrossRefPubMed
  12. ↵
    1. RECOVERY Collaborative Group
    . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397: 1637–1645. doi:10.1016/S0140-6736(21)00676-0
    OpenUrlCrossRefPubMed
  13. ↵
    1. RECOVERY Collaborative Group
    . Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022; 399: 665–676. doi:10.1016/S0140-6736(22)00163-5
    OpenUrlCrossRef
  14. ↵
    1. NHS England
    . UK Interim Clinical Commissioning Policy. Therapies for patients with symptomatic hospital-onset COVID-19. Date last updated: 27 January 2022. www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/12/C1572-interim-ccp-therapies-for-patients-with-symptomatic-hospital-onset-covid-19.pdf
  15. ↵
    1. Gupta A,
    2. Gonzalez-Rojas Y,
    3. Juarez E, et al.
    Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med 2021; 385: 1941–1950. doi:10.1056/NEJMoa2107934
    OpenUrlPubMed
  16. ↵
    1. Levin MJ,
    2. Ustianowski A,
    3. De Wit S, et al.
    Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med 2022; 386: 2188–2200. doi:10.1056/NEJMoa2116620
    OpenUrlPubMed
  17. ↵
    1. Jorgensen SCJ,
    2. Davis MR,
    3. Lapinsky SE
    . A review of remdesivir for COVID-19 in pregnancy and lactation. J Antimicrob Chemother 2021; 77: 24–30. doi:10.1093/jac/dkab311
    OpenUrl
  18. ↵
    1. Burwick RM,
    2. Yawetz S,
    3. Stephenson KE, et al.
    Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019. Clin Infect Dis 2021; 73: e3996–e4004. doi:10.1093/cid/ciaa1466
    OpenUrl
  19. ↵
    1. UK Obstetric Surveillance System (UKOSS)
    1. COVID-19 Clinical Information Network (CO-CIN)
    1. ISARIC4C Consortium
    , UK Obstetric Surveillance System (UKOSS), COVID-19 Clinical Information Network (CO-CIN). Females in hospital with SARS-CoV-2 infection, the association with pregnancy and pregnancy outcomes, 25 March 2021. Date last updated: 9 April 2021. www.gov.uk/government/publications/ukossisaricco-cin-females-in-hospital-with-sars-cov-2-infection-the-association-with-pregnancy-and-pregnancy-outcomes-25-march-2021
  20. ↵
    1. Favilli A,
    2. Gentili MM,
    3. Raspa F, et al.
    Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review. J Matern Fetal Neonatal Med 2022; 35: 2174–2187. doi:10.1080/14767058.2020.1774875
    OpenUrl
  21. ↵
    1. Räikkönen K,
    2. Gissler M,
    3. Kajantie E
    . Associations between maternal antenatal corticosteroid treatment and mental and behavioral disorders in children. JAMA 2020; 323: 1924–1933. doi:10.1001/jama.2020.3937
    OpenUrlCrossRefPubMed
  22. ↵
    1. Flint J,
    2. Panchal S,
    3. Hurrell A, et al.
    BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding – Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 2016; 55: 1693–1697. doi:10.1093/rheumatology/kev404
    OpenUrlCrossRefPubMed
  23. ↵
    1. Weinreich DM,
    2. Sivapalasingam S,
    3. Norton T, et al.
    REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med 2021; 385: e81. doi:10.1056/NEJMoa2108163
    OpenUrlCrossRefPubMed
    1. Folkman R,
    2. Blennow O,
    3. Tovatt T, et al.
    Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy. Infection 2022; in press [https://doi.org/10.1007/s15010-022-01829-4].
  24. ↵
    1. Mayer C,
    2. VanHise K,
    3. Caskey R, et al.
    Monoclonal antibodies casirivimab and imdevimab in pregnancy for coronavirus disease 2019 (COVID-19). Obstet Gynecol 2021; 138: 937–939. doi:10.1097/AOG.0000000000004603
    OpenUrlCrossRef
  25. ↵
    1. Hoffmann M,
    2. Krüger N,
    3. Schulz S, et al.
    The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell 2022; 185: 447–456.e11. doi:10.1016/j.cell.2021.12.032
    OpenUrlPubMed
  26. ↵
    1. Medicines and Healthcare Products Regulatory Agency
    . Summary of Product Characteristics for Evusheld. Date last updated: 17 March 2022. Date last accessed: 2 July 2022. www.gov.uk/government/publications/regulatory-approval-of-evusheld-tixagevimabcilgavimab/summary-of-product-characteristics-for-evusheld
  27. ↵
    1. Wiese MD,
    2. Berry MJ,
    3. Hissaria P, et al.
    COVID-19: can we treat the mother without harming her baby? J Dev Orig Health Dis 2022; 13: 9–19. doi:10.1017/S2040174420001403
    OpenUrl
  28. ↵
    1. Yu LM,
    2. Bafadhel M,
    3. Dorward J, et al.
    Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 2021; 398: 843–855. doi:10.1016/S0140-6736(21)01744-X
    OpenUrlCrossRefPubMed
  29. ↵
    1. UK Teratology Information Service
    . Use of inhaled corticosteroids in pregnancy. Date last updated: December 2016. Date last accessed: 2 July 2022. www.medicinesinpregnancy.org/bumps/monographs/use-of-inhaled-corticosteroids-in-pregnancy/
  30. ↵
    1. Hammond J,
    2. Leister-Tebbe H,
    3. Gardner A, et al.
    Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 2022; 386: 1397–1408. doi:10.1056/NEJMoa2118542
    OpenUrlCrossRefPubMed
  31. ↵
    1. Marconi VC,
    2. Ramanan AV,
    3. de Bono S, et al.
    Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 2021; 9: 1407–1418. doi:10.1016/S2213-2600(21)00331-3
    OpenUrl
  32. ↵
    1. Teratology Information Service
    1. UK
    Teratology Information Service. Medications used to treat COVID-19 in pregnancy. Date last updated: March 2022. Date last accessed: 2 July 2022. www.medicinesinpregnancy.org/bumps/monographs/medications-used-to-treat-covid-19-in-pregnancy/
  33. ↵
    1. Writing Committee for the REMAP-CAP Investigators
    . Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 2021; 326: 1690–1702. http://dx.doi.org/10.1001/jama.2021.18178.
    OpenUrlPubMed
  34. ↵
    1. Daru J,
    2. White K,
    3. Hunt BJ
    . COVID-19, thrombosis and pregnancy. Thrombosis Update 2021; 5: 100077. doi:10.1016/j.tru.2021.100077
    OpenUrl
  35. ↵
    1. Villar J,
    2. Ariff S,
    3. Gunier RB, et al.
    Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr 2021; 175: 817–826. doi:10.1001/jamapediatrics.2021.1050
    OpenUrl
  36. ↵
    COVID-19 Rapid Guideline: Managing the Long-term Effects of COVID-19. NICE Guideline No. 188. London, National Institute for Health and Care Excellence (NICE), 2020.
  37. ↵
    1. MBRRACE-UK
    . Saving lives, improving mothers’ care – lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2017–19. Date last updated: 11 November 2021. Date last accessed: 11 February 2022. www.npeu.ox.ac.uk/mbrrace-uk/reports
  38. ↵
    1. College of Obstetricians and Gynaecologists
    1. Royal
    College of Obstetricians and Gynaecologists. COVID-19 vaccines, pregnancy and breastfeeding FAQs. Date last updated: 20 December 2021. Date last accessed: 16 July 2022. www.rcog.org.uk/media/xypjjfw2/2021-12-21-combined-info-sheet-and-decision-aid.pdf
PreviousNext
Back to top
Vol 18 Issue 2 Table of Contents
Breathe: 18 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Managing COVID-19 in pregnant women
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Managing COVID-19 in pregnant women
Siara Teelucksingh, Melanie Nana, Catherine Nelson-Piercy
Breathe Jun 2022, 18 (2) 220019; DOI: 10.1183/20734735.0019-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Managing COVID-19 in pregnant women
Siara Teelucksingh, Melanie Nana, Catherine Nelson-Piercy
Breathe Jun 2022, 18 (2) 220019; DOI: 10.1183/20734735.0019-2022
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • COVID-19 in pregnancy
    • Severity of COVID-19 disease
    • Pharmacological management of COVID-19 in pregnancy
    • Maternal and fetal monitoring
    • Mode and timing of delivery
    • Follow-up
    • COVID-19 vaccination
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Assessing sleep disordered breathing in patients with heart failure
  • Choosing pharmacotherapy for ILD in patients with CTD
Show more Ask the expert

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society